» Articles » PMID: 30170533

Oral and Vaginal HIV Pre-exposure Prophylaxis Product Attribute Preferences Among Female Sex Workers in the Mexico-US Border Region

Overview
Journal Int J STD AIDS
Date 2018 Sep 2
PMID 30170533
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

To assess the potential uptake of HIV pre-exposure prophylaxis (PrEP) products among female sex workers (FSWs) vulnerable to HIV infection, we examined the influence of product attributes on willingness to use products among 271 HIV-negative FSWs in Tijuana and Ciudad Juarez, Mexico (2016-2017). Via five-point Likert scale ratings, participants indicated their willingness to use hypothetical products with six attributes: formulation (pill, gel, liquid, or ring), frequency of use (daily, on-demand, or monthly), cost per use (10 or 200 pesos), effectiveness (40% or 80%), side effects (none or mild), and access point (healthcare clinic or non-governmental organization). Conjoint analysis was used to determine the impact of attributes on product ratings and identify preferred product attributes. Multinomial logistic regression was used to identify factors associated with formulation preferences. In both cities, formulation and frequency of use had the greatest impact on ratings. Participants in Ciudad Juarez indicated a strong preference for oral pills, whereas participants in Tijuana indicated roughly equal preferences for oral pills and vaginal gels. Monthly product use was preferred in both cities. Compared to preferring oral pills (38%), preferring vaginal gels (28%) was associated with practicing vaginal lubrication (adjusted odds ratio = 2.08; 95% confidence interval: 1.07-4.04). Oral PrEP may be acceptable to many FSWs in Tijuana and Ciudad Juarez; however, continued development of behaviorally-congruent vaginal PrEP products may also facilitate uptake and ensure sufficient coverage.

Citing Articles

Perspectives and experiences regarding pre-exposure prophylaxis (PrEP) in a community sample of Veterans with unhealthy alcohol use: overall and across sexual orientation and gender identity.

Fletcher O, Beaver K, Austin E, Van Draanen J, Edelman E, Williams E Addict Sci Clin Pract. 2025; 20(1):5.

PMID: 39876005 PMC: 11773927. DOI: 10.1186/s13722-024-00533-y.


HIV Preexposure Prophylaxis Practice among Urban Female Sex Workers in Northwest Ethiopia: Using Generalized Structural Equation Modeling.

Asmare L, Goshu A, Alemu T, Gebeye E J Int Assoc Provid AIDS Care. 2024; 23:23259582241302900.

PMID: 39632570 PMC: 11618946. DOI: 10.1177/23259582241302900.


HIV pre-exposure prophylaxis programmatic preferences among people who inject drugs: findings from a discrete choice experiment.

Eger W, Bazzi A, Valasek C, Vera C, Harvey-Vera A, Strathdee S Addict Sci Clin Pract. 2024; 19(1):81.

PMID: 39533335 PMC: 11555929. DOI: 10.1186/s13722-024-00505-2.


Utilization of HIV Pre-exposure Prophylaxis and Associated Factors Among Female Sex Workers in Bahir Dar City, North-West Ethiopia, Cross-sectional Study, 2022.

Ademe B, Bogale E, Anagaw T Int J Gen Med. 2023; 16:6015-6024.

PMID: 38146329 PMC: 10749782. DOI: 10.2147/IJGM.S443477.


"Protected Means Armed": Perspectives on Pre-Exposure Prophylaxis (PrEP) Among Women Who Engage in Sex Work and Use Drugs in Kazakhstan.

McCrimmon T, Frye V, Darisheva M, Starbird L, Cordingley O, Terlikbayeva A AIDS Educ Prev. 2023; 35(5):347-361.

PMID: 37843909 PMC: 10901454. DOI: 10.1521/aeap.2023.35.5.347.


References
1.
Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-18. PMC: 4341965. DOI: 10.1056/NEJMoa1402269. View

2.
Bridges J, Hauber A, Marshall D, Lloyd A, Prosser L, Regier D . Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011; 14(4):403-13. DOI: 10.1016/j.jval.2010.11.013. View

3.
Van der Elst E, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P . High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2012; 17(6):2162-72. PMC: 3690654. DOI: 10.1007/s10461-012-0317-8. View

4.
Baeten J, Palanee-Phillips T, Brown E, Schwartz K, Soto-Torres L, Govender V . Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016; 375(22):2121-2132. PMC: 4993693. DOI: 10.1056/NEJMoa1506110. View

5.
Robertson A, Syvertsen J, Martinez G, Rangel M, Palinkas L, Stockman J . Acceptability of vaginal microbicides among female sex workers and their intimate male partners in two Mexico-US border cities: a mixed methods analysis. Glob Public Health. 2013; 8(5):619-33. PMC: 3674154. DOI: 10.1080/17441692.2012.762412. View